Protective effect of Flt3L on organ structure during advanced multiorgan dysfunction syndrome in mice

Tian,Guang; Lu,Jiangyang; Guo,Huiqin; Liu,Qian; Wang,Hongwei

doi:10.3892/mmr.2015.3328

Protective effect of Flt3L on organ structure during advanced multiorgan dysfunction syndrome in mice

Authors:
- Guang Tian
- Jiangyang Lu
- Huiqin Guo
- Qian Liu
- Hongwei Wang
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of General Hospital of PLA, Beijing 100048, P.R. China, Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing 100730, P.R. China
Published online on: February 10, 2015 https://doi.org/10.3892/mmr.2015.3328
Pages: 4135-4141
Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to examine whether fms‑related tyrosine kinase 3 ligand (Flt3L) protects the organs of mice with multiorgan dysfunction syndrome (MODS). Male C57BL/6 mice were randomly assigned to normal control, MODS and Flt3L treatment groups. The mouse models of MODS were established using intraperitoneal zymosan injections, followed by normal saline injections. The treatment group received 5 µg/kg Flt3L for seven days, beginning on day five following zymosan injection. On day 12, the mortality rates of the Flt3L treatment and the MODS groups were 7 and 18%, respectively. Marked pathological changes were observed in the liver, lungs, kidneys and heart of the mice with MODS, including degeneration and focal necrosis of parenchyma cells. Mild pathological changes were observed in different organs of the Flt3L‑treated mice. In the MODS group, the number of CD4+ T lymphocytes was significantly reduced, whereas the number of CD8+ T lymphocytes was significantly increased compared with that in the normal control group; thus, the CD4+/CD8+ ratio was reduced. In the Flt3L treatment group, the average number of CD4+ T lymphocytes was not significantly different to the average number of CD4+ T lymphocytes in the normal group. In conclusion, Flt3L administration improved the immune status and alleviated the organ damage in mice with late‑phase MODS.

View Figures

View References

1	Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J and Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 29:1303–1310. 2001. View Article : Google Scholar : PubMed/NCBI
2	Lawrence K: Pediatric sepsis and multiorgan dysfunction syndrome: progress and continued challenges. Crit Care Nurs Clin North Am. 23:323–337. 2011. View Article : Google Scholar : PubMed/NCBI
3	Bone RC, Sibbald WJ and Sprung CL: The ACCP/SCCM consensus conference on sepsis and organ failure. Chest. 101:1481–1483. 1992. View Article : Google Scholar : PubMed/NCBI
4	Davies MG and Hagen PO: Systemic inflammatory response syndrome. Br J Surg. 84:920–935. 1997. View Article : Google Scholar : PubMed/NCBI
5	Shimada H, Moriwaki Y, Kurosawa H, et al: Inflammatory mediator and organ dysfunction syndrome. Nippon Geka Gakkai Zasshi. 99:490–496. 1998.In Japanese.
6	Bone RC: Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med. 125:680–687. 1996. View Article : Google Scholar : PubMed/NCBI
7	Volk HD, Reinke P, Krausch D, et al: Monocyte deactivation - rationale for a new therapeutic strategy in sepsis. Intensive Care Med. 22(Suppl 4): S474–S481. 1996. View Article : Google Scholar
8	Mentula P, Kylänpää-Bäck ML, Kemppainen E, et al: Decreased HLA (human leucocyte antigen)-DR expression on peripheral blood monocytes predicts the development of organ failure in patients with acute pancreatitis. Clin Sci (Lond). 105:409–417. 2003. View Article : Google Scholar
9	Schefold JC: Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure. Intensive Care Med. 36:1810–1812. 2010. View Article : Google Scholar : PubMed/NCBI
10	Hotchkiss RS, Swanson PE, Freeman BD, et al: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 27:1230–1251. 1999. View Article : Google Scholar : PubMed/NCBI
11	Hotchkiss RS, Tinsley KW, Swanson PE, et al: Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol. 168:2493–2500. 2002. View Article : Google Scholar : PubMed/NCBI
12	Boomer JS, To K, Chang KC, et al: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 306:2594–2605. 2011. View Article : Google Scholar : PubMed/NCBI
13	Reddy RC, Chen GH, Tekchandani PK and Standiford TJ: Sepsis-induced immunosuppression: from bad to worse. Immunol Res. 24:273–287. 2001. View Article : Google Scholar
14	Monneret G, Debard AL, Venet F, et al: Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med. 31:2068–2071. 2003. View Article : Google Scholar : PubMed/NCBI
15	Jiangyang L, Qian L, Xiaohong W, et al: Changes of spleen dendritic cells in the terminal stage of multiple organ dysfunction syndrome. Acta Biomed. 82:146–153. 2011.
16	Shurin MR, Pandharipande PP, Zorina TD, et al: FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol. 179:174–184. 1997. View Article : Google Scholar : PubMed/NCBI
17	Sakabe H, Kimura T, Zeng Z, et al: Haematopoietic action of flt3 ligand on cord blood-derived CD34-positive cells expressing different levels of flt3 or c-kit tyrosine kinase receptor: comparison with stem cell factor. Eur J Haematol. 60:297–306. 1998. View Article : Google Scholar : PubMed/NCBI
18	Shaw SG, Maung AA, Steptoe RJ, Thomson AW and Vujanovic NL: Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol. 161:2817–2824. 1998.PubMed/NCBI
19	Wysocka M, Montaner LJ and Karp CL: Flt3 ligand treatment reverses endotoxin tolerance-related immunoparalysis. J Immunol. 174:7398–7402. 2005. View Article : Google Scholar : PubMed/NCBI
20	Flohé SB, Agrawal H, Schmitz D, Gertz M, Flohé S and Schade FU: Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J Leukoc Biol. 79:473–481. 2006. View Article : Google Scholar
21	Fujita S, Seino K, Sato K, et al: Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood. 107:3656–3664. 2006. View Article : Google Scholar : PubMed/NCBI
22	Wallet MA, Sen P and Tisch R: Immunoregulation of Dendritic Cells. Clin Med Res. 3:166–175. 2005. View Article : Google Scholar : PubMed/NCBI
23	Volman TJ, Hendriks T and Goris RJ: Zymosan induced generalized inflammation: experimental studies into mechanisms leading to multiple organ dysfunction syndrome. Shock. 23:291–297. 2005. View Article : Google Scholar : PubMed/NCBI
24	Zhang M, Tang H, Guo Z, et al: Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol. 5:1124–1133. 2004. View Article : Google Scholar : PubMed/NCBI
25	Tan C, Reddy V, Dannull J, et al: Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. J Transl Med. 11:1482013. View Article : Google Scholar : PubMed/NCBI
26	Fan X, Ye M, Xue B, Ke Y, Wong CK and Xie Y: Human dendritic cells engineered to secrete interleukin-18 activate MAGE-A3-specific cytotoxic T lymphocytes in vitro. Immunol Invest. 41:469–483. 2012. View Article : Google Scholar : PubMed/NCBI